ArticleDermatology and therapy2025
Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06415279 (Clinical Evaluation of the Sebum Reduction Induced by Clascoterone Cream 1%), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Evaluation of the Sebum Reduction Induced by Clascoterone Cream 1%
Who cites it
3 citing papers in PubMed.
- Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2026Review
- Validation of Madecassoside Synergy Significantly Enhanced Cryptotanshinone's Therapeutic Efficacy Against Acne Vulgaris.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn vitro, clascoterone inhibits androgen-induced sebum production-a key driver of acne pathogenesis-although the exact mechanism of action of clascoterone for the treatment of acne is unknown. This study evaluated reductions in casual sebum production following 12 weeks of clascoterone cream 1% treatment in patients with acne.
methodsPatients ≥ 12 years old with mild-to-moderate acne applied clascoterone cream 1% twice daily for 12 weeks. The primary endpoint was the reduction in casual sebum measurements at Week 12. Additional endpoints included Investigator's Global Assessment (IGA) score, inflammatory and noninflammatory lesion counts (ILC and NILC), and tolerability. Data were analyzed using Student's t-test and Wilcoxon signed-rank test.
resultsForty patients with a mean age of 20.9 years were enrolled, all of whom completed Week 12. Significant percentage reductions from baseline were observed in sebum measurements (27%), ILC (54%), and NILC (34%; all p < 0.001), and patients achieved a 29% reduction in IGA score. No tolerability or safety issues were identified during the 12-week interim analysis period.
conclusionClascoterone cream 1% led to significant reductions in sebum measurements with improvements in acne severity and was well tolerated.
trial registrationClinicalTrials.gov identifier, NCT06415279.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.